9 stories from 3 sources
Supporting Articles
Italy’s largest bank launched a €30.6bn bid for the world’s oldest bank, pitching the deal as a way to generate sizeable cost savings through consolidation. The offer would combine two major domestic lenders and accelerate reshaping of Italy’s banking sector.
9:57 AMFinancial TimesIntesa Sanpaolo offered €30.6 billion to buy Banca Monte dei Paschi di Siena, arriving a day after Banco BPM proposed a merger of equals with Monte Paschi. In consumer ingredients, Ingredion agreed to buy Tate & Lyle for £2.7 billion, ending Tate & Lyle’s long London listing.
5:20 AMBloomberg MarketsIntesa Sanpaolo offered to acquire Banca Monte dei Paschi di Siena for €30.6 billion, proposing 1.6 Intesa shares plus €1 in cash for each Monte Paschi share. The offer lands one day after Banco BPM floated its own merger pitch involving Monte Paschi.
1:51 AMBloomberg MarketsPatrick Drahi has agreed to sell French mobile carrier SFR to a consortium of rival telecom operators in a transaction valuing the company at about €20.4 billion. The deal sets up a major test of French and EU regulators' willingness to allow consolidation in a core infrastructure market.
3:54 AMBloomberg MarketsIngredion agreed to buy Tate & Lyle for £2.7 billion ($3.6 billion), ending Tate & Lyle's near-century listing on the London Stock Exchange. CEO James Zallie said Ingredion paid a fair premium and expects the combination to create a larger ingredients supplier with greater reach.
5:19 PMBloomberg MarketsIngredion agreed to acquire Tate & Lyle for £2.7 billion in a take-private deal. The transaction comes as Tate & Lyle faces pressure from subdued consumer spending.
5:15 AMFinancial TimesIngredion agreed to buy Tate & Lyle for £2.7 billion, ending the UK company’s near-century on the London Stock Exchange. The deal removes a long-standing consumer ingredients name from London’s public market.
2:10 AMBloomberg MarketsSummary
Italy’s largest bank launched a €30.6bn bid for the world’s oldest bank, pitching the deal as a way to generate sizeable cost savings through consolidation. The offer would combine two major domestic lenders and accelerate reshaping of Italy’s banking sector.
Why it matters
The bid tests how far Italy and EU regulators will let banks consolidate to improve profitability without destabilising competition, jobs, or financial resilience.
Summary
Intesa Sanpaolo offered €30.6 billion to buy Banca Monte dei Paschi di Siena, arriving a day after Banco BPM proposed a merger of equals with Monte Paschi. In consumer ingredients, Ingredion agreed to buy Tate & Lyle for £2.7 billion, ending Tate & Lyle’s long London listing.
Why it matters
Bank consolidation can change the cost and availability of working capital, while ingredients consolidation can raise input costs and reduce sourcing options for CPG supply chains.
Summary
Intesa Sanpaolo offered to acquire Banca Monte dei Paschi di Siena for €30.6 billion, proposing 1.6 Intesa shares plus €1 in cash for each Monte Paschi share. The offer lands one day after Banco BPM floated its own merger pitch involving Monte Paschi.
Why it matters
A bidding contest for Monte Paschi could redraw Italy’s banking hierarchy and reset M&A pricing across the sector.
Summary
Patrick Drahi has agreed to sell French mobile carrier SFR to a consortium of rival telecom operators in a transaction valuing the company at about €20.4 billion. The deal sets up a major test of French and EU regulators' willingness to allow consolidation in a core infrastructure market.
Why it matters
Approval could reset competitive dynamics in French telecom and become a template for wider European consolidation.
Summary
Ingredion agreed to buy Tate & Lyle for £2.7 billion ($3.6 billion), ending Tate & Lyle's near-century listing on the London Stock Exchange. CEO James Zallie said Ingredion paid a fair premium and expects the combination to create a larger ingredients supplier with greater reach.
Why it matters
A major consolidation in food ingredients can shift input costs and negotiating leverage across consumer packaged goods supply chains.
Summary
Ingredion agreed to acquire Tate & Lyle for £2.7 billion in a take-private deal. The transaction comes as Tate & Lyle faces pressure from subdued consumer spending.
Why it matters
Consolidation in ingredients can reshape pricing power and supply reliability for packaged food manufacturers.
Summary
Ingredion agreed to buy Tate & Lyle for £2.7 billion, ending the UK company’s near-century on the London Stock Exchange. The deal removes a long-standing consumer ingredients name from London’s public market.
Why it matters
A major ingredients business changing hands can alter competitive dynamics and contract leverage across the food and beverage supply chain.
A curated list of other prominent stories from this day.
AvalonBay and Equity Residential are structuring a merger of equals that splits leadership by function. AvalonBay executives will largely steer capital allocation, while Equity Residential executives will take key operations and legal roles.
1:10 PMHousing WireIncyte is close to acquiring blood disorder-focused biotech Star in a deal valued at up to $2bn. The transaction fits a broader push by midsized drugmakers to buy external assets to replenish pipelines and compete more effectively with larger pharmaceutical rivals.
8:40 AMFinancial TimesSummary
AvalonBay and Equity Residential are structuring a merger of equals that splits leadership by function. AvalonBay executives will largely steer capital allocation, while Equity Residential executives will take key operations and legal roles.
Why it matters
Who controls capital versus operations determines whether the combined REIT optimizes for near term earnings stability or for reallocation and growth.
Summary
Incyte is close to acquiring blood disorder-focused biotech Star in a deal valued at up to $2bn. The transaction fits a broader push by midsized drugmakers to buy external assets to replenish pipelines and compete more effectively with larger pharmaceutical rivals.
Why it matters
More M&A from midsize pharma can reset biotech valuations and accelerate consolidation around programs with credible paths to approval and commercialization.
Make it yours
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!